Haya Therapeutics, a Swiss‑US biotechnology company specialising in RNA‑guided therapeutics, has been awarded the Innosuisse Certificate for Sustainable Growth, according to the company.
The award includes CHF 1.5 million in non‑dilutive Start‑up Innovation Project funding from Innosuisse, the Swiss Innovation Agency. The company said that this funding will support translational research targeting cancer‑associated fibroblast‑specific long non‑coding RNA (lncRNA) for aggressive solid tumours over the next two years.
Haya said that its lncRNA platform enables precision targeting of regulatory RNAs to reprogram disease‑driving cell states. The company claims this approach has broad applicability beyond heart failure into oncology.
Funding will be allocated to developing a novel antisense therapy focused on the tumour microenvironment, specifically targeting cancer‑associated fibroblasts that contribute to fibrotic and immunosuppressive barriers in solid tumours.
This latest support complements Haya’s existing RNA‑guided pipeline, which includes HTX‑001 for heart failure and other preclinical candidates. The company claims the Innosuisse backing validates its growth potential and innovative RNA‑based modality.
Achievement of the Innosuisse certificate and accompanying funding underscores growing recognition of Haya’s technology and its efforts to translate regulatory genome targeting into disease‑modifying therapies.
